Jun. 1 at 4:22 PM
$NVAX the catalysts will come in due time, soon. Everyone here hates that word but it’s true. The institutional ownership increasing, lendable share shortage, impending analyst upgrades. These are things that happen before/during the squeeze. Remember to use this time to prepare your trading strategy so you can make profits on the squeeze. Don’t strike out looking. Don’t say “I’ll sell all my shares at
$X” because you likely won’t or it won’t go quite that high and you miss a major profit opportunity.
Remember, revenue guidance of
$230 million, and we already have
$140 in Q1. Sanofi technology transfer of
$75 and we are almost at full guidance. Easy beat for the year, without even getting Sanofi CIC P3
$125 million. But when we do get that, 🚀.
Any more MTA partnerships only adds to that squeeze. Plus Pfizer progress or naming diseases, plus any Sanofi Matrix M candidates named, plus potential Nova CIC/Flu partner. All of these are the bull thesis and it’s all very alive and well.
